Every 10-Q that Edgewell Personal Care Company (EPC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EPC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EPC filings page.
Edgewell Personal Care Company reported third‑quarter 2026 net sales of $570.1 million, up 1.7%, with net earnings from continuing operations of $12.3 million, or diluted EPS of $0.26. Organic net sales rose 1.1% as North America grew 3.0% and international markets declined 1.4%.
Gross margin from continuing operations fell to 42.5%, pressured by inflation, tariffs and mix, while adjusted gross margin slipped 30 basis points. Adjusted diluted EPS from continuing operations was flat year over year at $0.72, as lower gross profit and higher SG&A offset modest sales growth.
For the first nine months of fiscal 2026, Edgewell recorded a net loss of $62.6 million, versus net earnings of $56.0 million a year earlier. During the period the company booked a $37.4 million goodwill impairment and $71.9 million of restructuring and related charges tied to operating model changes and consolidation of Mexico and Wet Shave facilities. The sale of the Feminine Care segment to Essity generated approximately $340.0 million of proceeds; as of June 30, 2026, cash was $397.1 million and long‑term debt was $1,245.0 million.
Edgewell Personal Care Company reported Q2 fiscal 2026 net sales of $519.5 million, up 0.6% year over year, but profitability weakened. Net income from continuing operations fell to $4.0 million, or $0.09 diluted EPS, and total net loss was $10.6 million including discontinued operations.
The company closed the sale of its Feminine Care segment to Essity for approximately $340 million on a cash‑free, debt‑free basis, recording a $37.4 million goodwill impairment and a $2.2 million loss on assets held for sale. Feminine Care is now reported as discontinued operations.
Restructuring to streamline manufacturing and Wet Shave operations weighed on results, with $32.1 million restructuring charges in the first half and an expected $90 million of related charges in fiscal 2026. Adjusted diluted EPS from continuing operations was $0.60 for Q2 and $0.44 for the first six months, both below the prior-year periods despite slightly higher sales.
Edgewell Personal Care reported first‑quarter fiscal 2026 net sales of $422.8 million, up 1.9% year over year, but swung to a much larger loss. From continuing operations, the company posted a net loss of $29.2 million, with total net loss of $65.7 million including discontinued operations.
Results were hit by $18.1 million of restructuring charges and $5.8 million of related costs, plus a $37.4 million goodwill impairment and $3.8 million loss on assets held for sale tied to the divestiture of the Feminine Care segment. Gross profit fell to $161.0 million and gross margin declined as inflation, tariffs and lower volume outweighed productivity savings.
Wet Shave sales slipped to $291.3 million and segment profit declined to $42.2 million, while Sun and Skin Care sales rose 9.0% to $131.5 million but remained slightly unprofitable. Operating cash flow was negative $125.9 million, and total borrowings reached $1.56 billion, including $277.0 million drawn on the U.S. revolver. The sale of Feminine Care to Essity for about $340 million closed after quarter‑end and is earmarked primarily for debt reduction and reinvestment.